AstraZeneca /// Budesonida Inhalada . Los Hallazgos del Estudio Sugirieren Que Durante un Período de 28 días, el Medicamento Podría Reducir el Riesgo de Que los Pacientes Necesiten Tratamiento Hospitalario en un 90% .

Common Asthma Drug Lowers Risk of Covid-19 Hospitalisation, Oxford Study Finds .

A study from Oxford University has shown that a common asthma treatment can reduce the risk of hospitalisations by 90% among Covid-19 patients. 

The research, which was conducted in partnership with the NIHR Oxford Biomedical Research Centre and AstraZeneca, involved 146 participants. Half of those involved were given inhaled budesonide, which is usually used to treat the symptoms of asthma and chronic obstructive pulmonary disease, while the other half received standard patient care. 

Findings from the study, which were published earlier this month, suggested that over a 28-day period, the drug could reduce the risk of patients needing hospital treatment by 90%. The trial was sparked by data which suggested that patients who used inhaled steroids for other medical conditions were less likely to be admitted to hospital with Covid-19.  ...